The first aim of the partnership is the acceleration of TAmiRNA´s ongoing microRNA biomarker projects. The second is to offer one-stop biomarker development services to clients in need of diagnostic solutions for early diagnosis, prognosis, or patient stratification.
This partnership consolidates TAmiRNAs development pipeline and strengthens the competing power of SimplicityBio´s and TAmiRNA´s biomarker discovery and development services.
Moreover it will improve microRNA biomarker development and advance existing microRNA biomarker signatures to make them more sensitive, specific and robust.
SimplicityBio is Swiss based company, founded in 2015 and active in the discovery of novel medical biomarkers by means of its patented bioinformatics machine-learning technology. SimplicityBio aims to be the reference and improve drastically patient lives with new diagnostics enabling personalised medicine.